Back
18
Day Range
$167.58
$174.83
52-Week Range
$163.11
$315.35
Volume
2,041,871
50D / 200D Avg
$204.15
/
$245.83
Prev Close
$170.14
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (627 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 17.5 | 0.3 |
| P/B | 1.2 | 2.9 |
| ROE % | 7.0 | 3.7 |
| Net Margin % | 0.9 | 3.8 |
| Rev Growth 5Y % | 11.6 | 10.0 |
| D/E | 0.7 | 0.2 |
Analyst Price Target
Hold
$235.00
+36.4%
Low: $146.00
High: $345.00
Forward P/E
18.5
Forward EPS
$9.22
EPS Growth (est.)
+0.0%
Est. Revenue
160 B
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$41.63
$34.72 – $45.09
|
200 B | 5 |
| FY2029 |
$38.84
$32.40 – $42.06
|
190 B | 2 |
| FY2028 |
$26.37
$18.73 – $35.68
|
180 B | 7 |
Key Takeaways
Revenue grew 11.58% annually over 5 years — strong growth
Generating 375.00M in free cash flow
Capital efficient — spends only 0.42% of revenue on capex
ROIC of 3.56% — low return on invested capital
Growth
Revenue Growth (5Y)
11.58%
Revenue (1Y)10.06%
Earnings (1Y)-1.57%
FCF Growth (3Y)-64.51%
Quality
Return on Equity
6.98%
ROIC3.56%
Net Margin0.92%
Op. Margin1.12%
Safety
Debt / Equity
0.73
Current Ratio0.72
Interest Coverage2.30
Valuation
P/E Ratio
17.48
P/B Ratio1.18
EV/EBITDA20.31
Dividend Yield0.01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10.06% | Revenue Growth (3Y) | 10.37% |
| Earnings Growth (1Y) | -1.57% | Earnings Growth (3Y) | -30.91% |
| Revenue Growth (5Y) | 11.58% | Earnings Growth (5Y) | -20.22% |
| Profitability | |||
| Revenue (TTM) | 129.66B | Net Income (TTM) | 1.19B |
| ROE | 6.98% | ROA | 2.44% |
| Gross Margin | 14.54% | Operating Margin | 1.12% |
| Net Margin | 0.92% | Free Cash Flow (TTM) | 375.00M |
| ROIC | 3.56% | FCF Growth (3Y) | -64.51% |
| Safety | |||
| Debt / Equity | 0.73 | Current Ratio | 0.72 |
| Interest Coverage | 2.30 | Dividend Yield | 0.01% |
| Valuation | |||
| P/E Ratio | 17.48 | P/B Ratio | 1.18 |
| P/S Ratio | 0.16 | PEG Ratio | -18.57 |
| EV/EBITDA | 20.31 | Dividend Yield | 0.01% |
| Market Cap | 20.77B | Enterprise Value | 29.51B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 129.66B | 117.81B | 106.44B | 92.92B | 83.65B |
| Net Income | 1.19B | 1.21B | 2.49B | 2.81B | 2.93B |
| EPS (Diluted) | 9.84 | 9.98 | 20.00 | 22.08 | 22.67 |
| Gross Profit | 18.85B | 17.15B | 18.05B | 17.23B | 14.45B |
| Operating Income | 1.45B | 1.63B | 3.32B | 3.56B | 3.42B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 48.75B | 46.31B | 46.89B | 43.73B | 44.75B |
| Total Liabilities | 31.01B | 29.87B | 30.57B | 28.36B | 28.65B |
| Shareholders' Equity | 17.66B | 16.38B | 16.26B | 15.31B | 16.08B |
| Total Debt | 12.94B | 12.26B | 12.27B | 11.75B | 13.23B |
| Cash & Equivalents | 4.20B | 2.22B | 4.69B | 5.06B | 3.39B |
| Current Assets | 7.47B | 4.93B | 6.73B | 6.74B | 5.21B |
| Current Liabilities | 10.31B | 11.26B | 11.95B | 11.63B | 10.49B |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#475 of 618
Recent Activity
Entered
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026